HLX71 / Fosun Pharma - LARVOL DELTA

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Hengenix Biotech Inc | Not yet recruiting ➔ Completed | Trial primary completion date: Apr 2021 ➔ Jul 2021

Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • ANGPT1 • CRP

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Hengenix Biotech Inc

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease